Israel Englander’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Israel Englander’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-56,182	Closed	-$76K	–	8116
2021 Q4	$76K	Sell	56,182 -64,763	-54%	-$153K	﹤0.01%	6363
2021 Q3	$352K	Sell	120,945 -71,009	-37%	-$236K	﹤0.01%	5688
2021 Q2	$670K	Buy	+191,954	New	+$659K	﹤0.01%	5034
2021 Q1	–	Sell	-132,067	Closed	-$2.54M	–	6723
2020 Q4	$2.54M	Sell	132,067 -28,006	-17%	-$432K	﹤0.01%	3044
2020 Q3	$2.15K	Buy	160,073 +153,813	+2,457%	+$4.36M	﹤0.01%	2543
2020 Q2	$265K	Buy	+6,260	New	+$203K	﹤0.01%	3728
2019 Q4	–	Sell	-55,369	Closed	-$1.44M	–	4793
2019 Q3	$1.44M	Buy	55,369 +45,143	+441%	+$1.51M	﹤0.01%	2650
2019 Q2	$375K	Buy	+10,226	New	+$245K	﹤0.01%	3415
2018 Q1	–	Sell	-91,093	Closed	-$2.28M	–	4230
2017 Q4	$2.28M	Buy	+91,093	New	+$2.15M	﹤0.01%	2201

Other funds holding ODT

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Israel Englander's ODT Position: Q1 2022 in Review

Israel Englander sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 56,182 shares — an estimated $76K sold.

Israel Englander first reported a position in ODT in Q4 2017 and held it in 9 quarters. The position peaked at $2.54M in Q4 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

Israel Englander reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Israel Englander sold 56,182 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $76K.
Israel Englander first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Israel Englander's Odonate Therapeutics, Inc. Common Stock position peaked at $2.54M in Q4 2020.
8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Millennium Management's 13F filing for Q1 2022, filed 16 May 2022.